Glioblastoma Market Research Report - Forecast till 2030

Glioblastoma Market Research Report Information by Type (Primary Glioblastoma and Secondary Glioblastoma), by Treatment (Surgical Procedure, Radiation Therapy, Chemotherapy and others), by End User (Hospitals, Specialty Clinics & Centers and others) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2030

ID: MRFR/HC/6835-CR | 133 Pages | Author: Kinjoll Dey | September 2019         

Glioblastoma Market Speak to Analyst Request a Free Sample

Global Glioblastoma Market Overview

Glioblastoma Market is expected to register a CAGR of 7.60% to reach USD 2416.33 million by 2030. Glioblastoma is a type of brain tumor.The increasing occurrences of glioblastoma, a type of brain tumor, coupled with extensive research in glioblastoma treatment, and the rising adoption of chemotherapy are expected to fuel the growth of the glioblastoma market. However, the high cost of drugs and the failure of drug candidates in clinical trial phases are anticipated to hamper the market growth.

Glioblastoma Market Trends

The increasing incidence rate of glioblastoma is expected to fuel the growth of the glioblastoma market. According to the statistics published in 2017 by the National Centre for Biotechnology Information (NCBI), glioblastoma has an incidence rate of 3.19 per 100,000 persons in the US. The growing prevalence indirectly increases the healthcare expenditure of the people as well as the government. This motivates the players operating in the market to come up with alternatives for the treatment of glioblastoma. Thus, this is likely to fuel the growth of the global glioblastoma market during the forecast period.

Glioblastoma Global Market Share, by End User, 2018 (%)  Glioblastoma Market

Source: MRFR Analysis

Glioblastoma Market Segment Insights

The global glioblastoma market has been segmented by type, treatment, and end user. The market, based on type, has been bifurcated into primary glioblastoma and secondary glioblastoma. Based on treatment, the glioblastoma market has been segregated into surgical procedure, radiation therapy, chemotherapy, and others. The global glioblastoma market, based on end user, has been divided into hospitals, specialty clinics and centers, and others. The specialty clinics and centers held a share of 36.8% in 2018.

Western Europe Glioblastoma Market Share,  (%)Glioblastoma Market

Source: MRFR Analysis

Glioblastoma Regional Insights

The glioblastoma global market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to dominate the global glioblastoma industry. The growth in this region can be attributed to the increased cases of glioblastoma and brain tumors. Moreover, the approval of drugs helps in maximizing the growth of the market in this region.

Europe held a substantial share in the global glioblastoma market. This can be attributed to a large number of clinical trials in the region. For instance, Merck KGaA along with Vaximm GmbH is involved in Phase I and II trials to evaluate the efficacy and safety of VXM01 in combination with Avelumab in patients with resectable and non-resectable progressive glioblastoma following tumor resection and radio-chemotherapy containing temozolomide.

Asia-Pacific is estimated to be the fastest-growing region in the global market. The rise in the improved healthcare infrastructure promises a high level of research on the treatment of glioblastoma in the region.

The glioblastoma market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth in this region. Rising awareness regarding health and availability of new treatment methods are expected to drive the market growth during the assessment period.

Key Players

The prominent players in the global glioblastoma market are F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel).

Some of the key strategies followed by players operating in the global glioblastoma market were innovation, product development, and acquisition & mergers.

  • In May 2019 Merck entered into a definitive agreement to acquire Peloton Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company, focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.

  • In January 2018 Amgen and Allergan PLC received the approval by the European Commission (EC) for the marketing authorization of MVASI for the treatment of glioblastoma as well as certain types of cancers.

  • In November 2016 Sun Pharma acquired Biosintez, a Russian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical products.

Glioblastoma Market Segmentation

Glioblastoma Type Outlook

  • Primary Glioblastoma

  • Secondary Glioblastoma

Glioblastoma Treatment Outlook

  • Surgical Procedure

  • Radiation Therapy

  • Chemotherapy

  • Others

Glioblastoma End User Outlook

  • Hospitals

  • Specialty Clinics and Centers

  • Others

Glioblastoma Region Outlook

  • Americas

    • North America

      • US

      • Canada

    • Latin America

  • Europe

    • Western Europe

      • Germany

      • UK

      • France

      • Italy

      • Spain

      • Rest of Western Europe

    • Eastern Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • Middle East

    • Africa

Available Additional Customizations

  • Mega Trends in the Market

  • Glioblastoma Market: Challenges

Intended Audience

  • Pharmaceutical companies

  • Contract research manufacturing organizations

  • Research & development organizations

  • Academic institutes

Report Scope:

Report Attribute/Metric Details
  Market Size   2416.33 Million
  CAGR   7.60%
  Base Year   2021
  Forecast Period   2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Treatment , End User and Region
  Geographies Covered  North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors  F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (US), Merck & Co., Inc. (US), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (US), and Teva Pharmaceutical Industries Ltd (Israel)
  Key Market Opportunities ·  The high cost of drugs. ·  Failure of drug candidates in clinical trial phases.
  Key Market Drivers   Increases the healthcare expenditure

Frequently Asked Questions (FAQ) :

glioblastoma market is expected to reach a valuation of USD 2416.33 bmllion by 2030.

The global market is expected to exhibit a strong 7.60% CAGR over the forecast period from 2020 to 2030.

The growing prevalence of glioblastoma is the major driver for the global market.

The Americas are likely to dominate the global glioblastoma market.

Leading players in the market include F. Hoffman-La Roche, Merck, and Amgen, among others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response